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Blood platelets play an essential role in ischemic heart
disease and stroke contributing to acute thrombotic
events by release of potent inflammatory agents within
the vasculature. Lysophosphatidic acid (LPA) is a bioac-
tive lipid mediator produced by platelets and found in
the blood and atherosclerotic plaques. LPA receptors on
platelets, leukocytes, endothelial cells, and smooth mus-
cle cells regulate growth, differentiation, survival, mo-
tility, and contractile activity. Definition of the oppos-
ing pathways of synthesis and degradation that control
extracellular LPA levels is critical to understanding
how LPA bioactivity is regulated. We show that intact
platelets and platelet membranes actively dephospho-
rylate LPA and identify the major enzyme responsible as
lipid phosphate phosphatase 1 (LPP1). Localization of
LPP1 to the platelet surface is increased by exposure to
LPA. A novel receptor-inactive sn-3-substituted diflu-
oromethylenephosphonate analog of phosphatidic acid
that is a potent competitive inhibitor of LPP1 activity
potentiates platelet aggregation and shape change re-
sponses to LPA and amplifies LPA production by ago-
nist-stimulated platelets. Our results identify LPP1 as a
pivotal regulator of LPA signaling in the cardiovascular
system. These findings are consistent with genetic and
cell biological evidence implicating LPPs as negative
regulators of lysophospholipid signaling and suggest
that the mechanisms involve both attenuation of lyso-
phospholipid actions at cell surface receptors and oppo-
sition of lysophospholipid production.
Lysophosphatidic acid (1-acylglycerol-3-phosphate, LPA)1 is
the prototypic member of a class of receptor-active lipid phos-
phoric acid mediators that function as intercellular signaling
molecules. LPA and the structurally related compound sphin-
gosine 1-phosphate (S1P) are present in biological fluids at
physiologically relevant concentrations and exert many of their
effects on target cells by binding to specific heterotrimeric
GTP-binding protein (G-protein)-coupled cell surface receptors.
Responses to stimulation with LPA and S1P include growth,
differentiation, chemotaxis, smooth muscle contraction, and
changes in cell morphology and motility through alterations in
organization of the actin cytoskeleton (1–3).
Blood plasma contains physiologically relevant levels of LPA
(4). Because of the multiple actions of LPA on cells of the
vasculature, a growing body of evidence suggests that LPA
plays an important role in blood clotting, wound healing, and
tissue regeneration (3). The mitogenic and chemotactic actions
of LPA may also participate in the recruitment of monocytes
and macrophages and aberrant stimulation of endothelial and
vascular muscle cell growth that underlie intimal hyperplasia,
formation of an atherosclerotic plaque, and progression of ath-
erosclerosis (5). Elevated plasma levels of LPA have also been
associated with ovarian and certain other gynecological can-
cers, where LPA may participate in autocrine or paracrine
stimulation of tumor cell growth (6).
LPA is a major growth factor in serum where it is produced
by pathways that are initiated by platelet activation. Platelets
also appear to play a central role in the production of LPA in
the blood (7, 8). One pathway for LPA synthesis involves the
actions of a secretory phospholipase A2 on phosphatidic acid
(PA)-enriched membrane microparticles that are released from
activated platelets (9). Another pathway involves formation of
lysophosphatidylcholine by lecithin cholesterol acyl transferase
or release of this lipid by platelets and other blood cells, which
is then converted to LPA by the lysophosphatidylcholine-selec-
tive lysophospholipase D activity of autotaxin (10–12).
Platelets are highly responsive to LPA. Exposure of resting
platelets to LPA elicits rapid shape change, actin reorganiza-
tion, aggregation, and fibronectin matrix assembly (3, 5, 13).
Enzymatic dephosphorylation terminates the signaling actions
of LPA (14). The major activities responsible are lipid phos-
phate phosphatases (LPPs), which are integral membrane en-
zymes with specificity for LPA, S1P, and related lipid mono-
phosphates (15–18). LPPs localize to the plasma membrane
and to intracellular membrane compartments. When in the
plasma membrane, the active sites of these enzymes are ori-
ented toward the extracellular space (18–20). Genetic and cell
biological evidence identifies roles for LPPs in both intracellu-
lar lipid metabolism and as negative regulators of lysophospho-
lipid signaling, although the mechanisms involved remain to be
firmly established (19, 21–25).
Here we show that a specific LPP isoform, LPP1, is strongly
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expressed in platelets and that its localization and activity are
regulated by platelet agonists. Newly synthesized chemical
inhibitors identify LPP1 as a global regulator of LPA produc-
tion and signaling in platelets. The dual function of LPP1 as a
regulator of both LPA production and responsiveness may ex-
plain the complex and pleiotropic phenotypes associated with
overexpression, misexpression, or down-regulation of this class
of enzymes in many systems (19, 21, 25–28).
EXPERIMENTAL PROCEDURES
General Procedures and Reagents—Unless otherwise stated, re-
agents used in this study were from previously identified sources. SDS-
PAGE and Western blotting were performed as described previously
(18, 20, 29).
Expression and Purification of LPP Enzymes—LPP1, LPP2, LPP3,
and His6-tagged LPP1 were expressed in insect cells using baculovirus
vectors, and membranes were prepared from these cells and used as
sources of recombinant LPP proteins for Western blots and activity
assays as described previously (18, 20, 29).
Preparation of Substrates—Unlabeled PA and LPA with acyl chain
configurations as specified were from Avanti Polar Lipids (Alabaster,
AL). Radiolabeled lipid substrates were prepared as described previ-
ously (18). 1-Oleoyl[oleoyl-9,10-3H(N)]lysophosphatidic acid was ob-
tained from PerkinElmer Life Sciences, Boston, MA.
Lipid Phosphatase Assays—Dephosphorylation of radiolabeled or un-
labeled lipid substrates presented in detergent micelles with Triton
X-100 or complexed with fatty acid-free BSA as described previously
(18, 20).
Synthetic LPA and PA Analogs—The synthesis of the compounds
used in this study has been described in detail elsewhere (30–32).
Isolation of Human Platelets and Microvesicles—Blood was collected
from healthy aspirin-free donors, and platelet-rich plasma was pre-
pared by centrifugation. For most experiments, platelets were sepa-
rated from citrated plasma by gel-filtration through Sepharose 2B in
Tyrode’s buffer (138 mM NaCl, 2.7 mM KCl, 0.4 mM NaH2PO4, 12 mM
NaHCO3, 10 mM HEPES, 0.35% BSA, 0.1% glucose, pH 7.4). Aggrega-
tion of gel-filtered platelets (1–3  108/ml) was performed as previously
described (33). For isolation of microvesicles, platelets were resus-
pended in Tyrode’s buffer containing 2 mM CaCl2 and incubated with 19
M A23187 and 100 nM phorbol 12-myristate 13-acetate at 37 °C for 30
min. Intact platelets were sedimented at 2000  g for 20 min at room
temperature, and microvesicles were recovered by centrifugation of the
supernatant at 100,000  g for 20 min.
Antibodies—A peptide corresponding to residues 254–267 (FFK-
ERTSFKERKE) of the sequence of human LPP1 was synthesized and
used as a conjugated antigen for production of an affinity-purified
rabbit antibody using the procedure previously described for the LPP3
antibody (20).
Surface-labeling Platelets with Biotin—Washed platelets were sus-
pended in Tyrode’s buffer at 5  108/ml and then mixed with an equal
volume of Sulfo-N-Hydroxysuccimido-biotin (1 mg/ml) in Tyrode’s
buffer. The mixture was incubated at room temperature with constant
rocking for 30 min. Platelets were washed twice with Tyrode’s buffer
containing 1 mM glycine and then suspended in buffer A and 2% Triton
X-100 and incubated at 4 °C for 1 h with constant rocking. The material
was centrifuged at 25,000  g at 4 °C for 30 min. The supernatant was
mixed with 8 units of avidin-Sepharose and rocked at 4 °C for 1 h. The
resin was sedimented by gentle centrifugation and washed six times by
resuspension in 100 volumes of ice-cold lysis buffer containing 2%
Triton X-100. The avidin-Sepharose was resuspended in lysis buffer for
determination of LPA phosphatase activity or boiled in SDS-PAGE
sample buffer for analysis of proteins by Western blotting.
Sucrose Density Gradient Fractionation—Outdated platelets were
washed and disrupted by nitrogen cavitation as previously described
(33). A stepwise sucrose gradient (from 0.8 to 2.0 M sucrose in incre-
ments of 0.2 M) was used to subfractionate the platelet lysate. The
platelet lysate was layered on top of the gradient and centrifuged at
100,000  g and 4 °C for 60 min in a SW-41 rotor (Beckman Instru-
ments; Palo Alto, CA). A volume containing 30 g of the indicated
fractions was separated on a 10% SDS-PAGE. The relative concentra-
tions of the well-characterized platelet membrane proteins GPIIIa,
-granule P-selectin, and LPP1 were determined by immunoblotting
and scanning densitometry.
Enzymatic Deglycosylation—Proteins were subjected to enzymatic
deglycosylation using previously described procedures or modifications
of procedures provided by the manufacturer (20). The enzymes used
were obtained from Calbiochem, San Diego, CA.
Fluorescence Microscopy—Fibrinogen (100 g/ml) was immobilized
on Lab-Tek chamber slides (Nunc, Inc., Rochester, NY) overnight at
4 °C, and nonspecific sites were blocked with BSA. Gel-filtered platelets
(25,000–50,000/ml in Tyrode’s buffer containing 1 mM MgCl2) were
incubated with the fibrinogen-coated slides in the absence or presence
of 10 M ADP or 1 M LPA for 30 min at room temperature (22 °C).
The wells were washed by inversion, and the adherent platelets were
stained for 30 min at RT with either monoclonal antibody 10E5 against
IIb3 or monoclonal antibody 6F1 against 21, or control antibody
(34). Platelets were fixed with 4% paraformaldehyde in PBS for 20 min
at RT and permeabilized with 0.1% Triton X-100 in PBS for 10 min at
RT. After washing, the fixed, permeabilized platelets were incubated in
the dark with TRITC-phalloidin (0.025 g/ml in PBS, Sigma Chemical
Co.) antibodies specific for LPP1 or LPP3 and the appropriate fluores-
cein isothiocyanate-labeled secondary antibody. Slides were mounted
with Prolong AntiFade (Molecular Probes) and examined with a Nikon
Eclipse 800 microscope. Digital images were captured and scored by a
blinded reviewer for the number of adherent platelets/high power field
and the percentage of spread platelets/high power field. Spread plate-
lets were identified by TRITC-phalloidin staining of actin fibers.
Rho Activation Assays—Platelets were incubated in 100-mm diame-
ter dishes that had been coated with 100 g/ml fibrinogen as described
above. Rho activation was measured using a rhotekin binding assay
(Upstate Biotechnology Inc.) following the manufacturer’s instructions.
Total and active Rho were detected by SDS-PAGE and Western blotting
of total lysate and rhotekin-bound proteins, respectively, and quanti-
tated by scanning densitometry.
Measurement of LPA Production by Platelets—LPA production by
washed platelets was determined using minor modifications of a re-
cently published procedure (10). In brief, gel-filtered platelets were
washed and then resuspended in phosphate-free Tyrode’s buffer con-
taining 2 mCi of [32P]PO4
2 and 1 M prostaglandin E1 at 2  109
platelets/ml. The platelet suspension was incubated for 3 h at 37 °C in
a shaking water bath. Platelets were sedimented by gentle centrifuga-
tion, the labeling medium was removed, and the platelets were washed
twice in Tyrode’s buffer containing 1 M prostaglandin E1 before resus-
pension in this buffer to a final density of 2  108 platelets/ml. 0.5-ml
incubations were initiated by combining 0.25 ml of platelet suspension
with 0.25 ml of Tyrode’s buffer supplemented with 2 mM CaCl2 and
containing combinations of 10 M TRAP (thrombin receptor-activating
peptide SFLLRN) with 10 M XY-14. 37 °C incubations in a gently
shaking water bath were terminated by microcentrifugation. Lipids
were extracted from the supernatant and separated by thin layer chro-
matography as described (10). [32P]LPA was identified by co-migration
with a radiolabeled standard run in parallel and quantitated using a
STORM PhosphorImager system.
Statistical Analysis—Results are expressed as the mean  S.D.
unless otherwise indicated and, where appropriate, analyzed by Stu-
dent t test.
RESULTS
Characterization of LPP Activities in Intact Platelets and
Platelet-derived Fractions—When gel-filtered human platelets
were incubated with 10 M [32P]oleyl-LPA in a final concentra-
tion of 0.1% fatty acid-free BSA, we observed rapid time-
dependent release of ammonium molybdate-extractable
[32P]PO4
2, which occurred without significant uptake of the
substrate by the platelets. When this experiment was repeated
using a mixture of [32P]oleyl-LPA and oleyl-LPA that was la-
beled with 3H in the acyl chain, we found that greater than 95%
LPA was converted to a stoichiometric mixture of monoacyl-
glycerol and PO4
2 and that the kinetics of accumulation of
these products were identical. Taken together, these results
show that intact platelets contain a surface phosphatase that
actively dephosphorylates LPA to generate the receptor-inac-
tive molecule monoacylglycerol. To probe the substrate speci-
ficity of this phosphatase activity, we examined dephosphoryl-
ation of LPA, PA, and S1P by intact platelets, platelets that
had been disrupted by brief probe sonication, and platelet-
derived membrane microvesicles. Intact platelets dephospho-
rylated all three substrates, and the rate of dephosphorylation
of LPA was approximately four times greater than that ob-
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served with PA and six times greater than observed with S1P.
When platelets were disrupted by sonication, the rate of de-
phosphorylation of LPA was approximately doubled suggesting
that most of the activity responsible was at the platelet surface.
The microvesicle preparations contained 20% of the LPA
phosphatase activity of the platelets from which they were
derived (Table I). Using mixed substrate and Triton X-100
micelles, we found that LPA, PA, and S1P phosphatase activ-
ities were predominantly membrane-associated in platelets,
were stimulated by Triton X-100, were independent of Mg2,
and were insensitive to inhibition by N-ethylmaleimide (NEM),
all of which are characteristic properties of the LPP enzymes
(14) (Table II).
Immunological Analysis of LPPs in Platelets—We previously
reported a selective antibody for LPP3 (20). We raised an
antibody against LPP1 by immunization of rabbits with a pep-
tide corresponding to a unique internal sequence (Fig. 1A). This
antibody selectively recognizes LPP1 expressed in sf9 cells
using a baculovirus vector in Western blots (Fig. 1B) and effi-
ciently immunoprecipitates LPP1 but not LPP2 or LPP3 activ-
ity from detergent extracts of membranes from insect cells
infected with these vectors (Fig. 1C). Detergent extracts from
platelet membranes were analyzed by immunoprecipitation
using the LPP1 and LPP3 antibodies. Although immunopre-
cipitation using an irrelevant control antibody resulted in no
loss of LPP activity from the extracts, immunoprecipitation
with the LPP1 antibody resulted in depletion of 87  0 3.1% of
LPP activity. By contrast, immunoprecipitation with the LPP3
antibody depleted only 4.5  0.7% of the activity (means 
S.D., n  3). In agreement with these findings, LPA phospha-
tase activity in the immune complexes from the LPP1 immu-
noprecipitation was 16-fold higher than that recovered after
immunoprecipitation with the LPP3 antibody (Fig. 1D). West-
ern blot analysis of detergent extracts of platelet membranes
using the LPP1 antibody described above detected a strongly
reacting protein species with a molecular mass of 34 kDa and
a less abundant species with a molecular mass of 31 kDa.
LPPs are extremely hydrophobic and it is likely that the minor
immunoreactive species with higher molecular weight repre-
sent aggregated forms of the proteins. Human LPP1 has a
TABLE II
Biochemical characterization of LPP activities in platelet fractions
Washed platelets were disrupted by sonication and separated into
cytosolic and membrane fractions by differential centrifugation. Phos-
phatase activities were determined using radiolabeled substrates pre-
sented in mixed micelles with Triton X-100 as described in the text. The
final Triton X-100 concentration was 3.2 mM, and the final substrate
concentration was 100 M. Assays contained 5 mM EDTA or 5 mM
MgCl2. In some cases samples were preincubated with 5 mM NEM
before addition to the assays. The data shown were obtained using
fractions isolated from platelets obtained from the blood bank and are
representative of three separate experiments.
Phosphatase activity (mean  S.D., n  3)
Substrate Mg2 Mg2 NEM
pmol/mln/106 platelets
Cytosol PA 0.02  0.01 0.14  0.02 0.02  0.01
LPA 0.21  0.2 1.80  0.3 0.19  0.03
S1P ND ND ND
Membranes PA 8.9  1.2 9.0  1.3 7.6  2.1
LPA 14.1  0.36 13.1  2.0 12.9  1.5
S1P 2.8  0.2 2.7  0.3 2.3  0.3
FIG. 1. Immunological analysis of LPP expression in platelets.
A, the sequences of human LPP1, LPP2, and LPP3 are shown aligned.
The sequence used for the synthetic peptide used to generate the
LPP1-selective antibody is underlined. B, detergent extracts of mem-
branes from sf9 cells expressing LPP1, LPP2, and LPP3 were separated
by SDS-PAGE on a 12.5% gel. Immunoreactive proteins were visualized
by Western blotting using the LPP1-selective antibody as described in
the text. C, LPP1, LPP2, and LPP3 were expressed in insect cells using
baculovirus vectors, and membrane proteins were extracted with deter-
gent and subjected to immunoprecipitation using the LPP1-selective
antibody. LPP activity was determined in the immune complexes as
described in the text. The data shown are means  S.D. of triplicate
assays from a single experiment. D, platelet membrane proteins were
extracted with detergent and subjected to immunoprecipitation using
control, LPP1-, and LPP3-selective antibodies. LPP activity was deter-
mined in the immune complexes as described in the text. The data
shown are means  S.D. of triplicate assays from a single experiment.
E, platelet membrane proteins were extracted with detergent and sep-
arated by SDS-PAGE on a 12.5% gel before Western blotting using an
LPP1-selective antibody as described in the text. Samples were
untreated (U) or treated with protein deglycosylation enzymes as indi-
cated: NGF, endo--N-acetylgalactosaminidase; ENDO-, 2–3,6,8,9-
neuraminidase; -N, G/N, 1,4-galactosidase, or -N-acetylglu-
cosaminidase, or all these enzymes in combination. F, platelet
membrane proteins were extracted, separated by SDS-PAGE, and an-
alyzed by Western blotting with an LPP3-selective antibody.
TABLE I
Properties of LPP activities in intact platelets and platelet fractions
Freshly isolated gel-filtered platelets prepared in the presence of
PGI2 were incubated at 37 °C in Tyrode’s solution containing 1 M
[32P]oleyl-LPA. Dephosphorylation was quantitated by measuring for-
mation of [32P] PO4
2. In one series of assays, the platelets were dis-
rupted by brief probe sonication before addition to the assays. In an-
other series, platelets were stimulated with phorbol ester and Ca2
ionophore and sedimented by centrifugation. LPA phosphatase activity
was determined in membrane microvesicles released by the activated
platelets, which were recovered from the supernatant. These are rep-
resentative data from one series of experiments using platelets from the
same donor. We did not observe significant differences in lipid phos-
phatase activities in platelet samples isolated from different donors.
Phosphatase activity (mean  S.D., n  3)
LPA PA S1P
pmol/min/109 platelets
Intact platelets 4.62  0.16 1.20  0.03 0.76  0.13
Sonicated platelets 8.66  0.17 1.21  0.05 3.78  0.14
Microvesicles 1.71  0.13 0.15  0.03 0.10  0.01
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predicted molecular mass of 31.9 kDa. All LPP isoforms contain
a single functional consensus glycosylation sequence in the loop
between transmembrane regions three and four. Glycosylated
LPPs have been shown to be sensitive to treatment with N-
glycanase and sialidase (14, 20). We found that treatment of
samples with N-gycosidase F increased electrophoretic mobil-
ity of the 34-kDa species, but no increase in mobility was
observed when samples were treated with endo--N-acetyl-
galactosaminidase, 2–3,6,8,9-neuraminidase, 1,4-galactosid-
ase, or -N-acetylglucosaminidase. These results suggest that
platelet LPP1 is modified by N-linked glycosylation. Mobility of
the less abundant immunoreactive species was unaltered by
these treatments, so this may represent a nonglycosylated form
of the protein (Fig. 1E). We detected a less abundant 35-kDa
immunoreactive protein when platelet membrane extracts
were probed using an LPP3-specific antibody. Taken together,
these results suggest that LPP1 accounts for the major LPP
activity in human platelets and platelets also express LPP3 at
a much lower level (Fig. 1F).
Distinct Localization Patterns of LPP1 and LPP3 in Resting
and LPA-stimulated Adherent Platelets—We used indirect im-
munofluorescence to examine the distribution of LPP1 in fixed
platelets adherent to fibrinogen. These experiments revealed
that in unstimulated platelets LPP1 localized to the platelet
surface and possibly also intracellular membrane structures.
Stimulation of platelets with LPA resulted in dramatic platelet
spreading, which was accompanied by concomitant expansion
of LPP1 distribution across the platelet surface (Fig. 2, A and
B). LPP1 was not distributed evenly in resting or stimulated
platelets but displayed a punctate localization pattern. LPP1
localization was distinct from that of two other platelet surface
proteins IIb3 and 21 (not shown, but see Fig. 2, C–E).
Similar changes in LPP distribution were observed when plate-
lets were stimulated with the thrombin receptor-activating
peptide TRAP or with ADP (not shown). Unexpectedly, staining
platelets with the LPP3 antibody revealed that the apparently
low levels of expression of this LPP isoform observed by West-
ern blotting arise not from uniformly low expression in the
entire platelet population but because LPP3 is strongly ex-
pressed in 5% of the platelets (Fig. 2, C and D). In LPA-
activated platelets, LPP3 localized both to the center of the
platelet and to the platelet periphery. Interestingly, the local-
ization pattern of LPP3 was very similar to that of IIb3 (Fig.
2E). LPP3 has recently been noted to contain an RGD sequence
that interacts with 3 integrins and was therefore postulated to
function in cell-cell interactions (26). Our results are consistent
FIG. 2. Localization of LPP1 and
LPP3 in resting and LPA-stimulated
platelets. Platelets were incubated with
fibrinogen-coated slides under resting
conditions (A) or with stimulation by 1 M
LPA (B). The platelets were fixed and
stained with antibodies against LPP1.
Immunoreactive proteins were visualized
using a fluorescein isothiocyanate-conju-
gated secondary antibody (right panel),
and actin organization was simulta-
neously analyzed by staining with Rho-
damine-conjugated phalloidin (Left pan-
el). C–E, platelets were incubated with
fibrinogen-coated slides in the presence of
1 M LPA. Platelets were fixed and
stained with antibodies against LPP3 or
IIb3 as indicated. Actin organization was
simultaneously visualized by staining
with rhodamine-conjugated phalloidin.
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with an interaction between LPP3 and IIb3 that may deter-
mine the lateral organization of LPP3 in the platelet
membrane.
Recovery of LPP1 Protein and Activity after Surface Biotiny-
lation of Resting and Stimulated Platelets—Because of their
small size, application of high resolution imaging strategies to
resolve internal and surface proteins in platelets is technically
challenging. To directly evaluate localization of LPP1 to the
platelet surface, we examined susceptibility of the protein to
labeling with a cell impermeant biotin derivative. Although
biotinylation resulted in a modest (25%) decrease in LPP
activity measured in detergent extracts from either resting or
LPA-activated platelets, exposure to this reagent did not mea-
surably effect the ability of our LPP1 antibody to detect the
protein in Western blots (Fig. 3, A and B). 58% of the extracted
LPP activity could be captured by avidin-Sepharose after sur-
face biotinylation of resting platelets, and this value was in-
creased to 93% in platelets that were stimulated with LPA. In
agreement with these activity measurements, in comparison to
resting platelets we saw a proportionate increase in the
amount of immunoreactive LPP1 that was captured from LPA-
stimulated platelets (Fig. 3, A and B). Taken together with our
observations that intact platelets dephosphorylate LPA, these
results indicate that LPP1 is present at the surface of resting
platelets and suggest that the redistribution of LPP1 across the
surface of activated platelets observed in the immunofluores-
cence studies is accompanied by an increase in surface local-
ization of the protein. Fractionation of platelet membranes by
sucrose density gradient centrifugation revealed that the ma-
jority of LPP1 was in plasma membrane and -granule frac-
tions (Fig. 3C). The presence of LPP1 in -granules could ex-
plain the re-distribution of LPP1 after agonist stimulation of
platelets, because these granules fuse with the plasma mem-
brane following platelet activation.
Identification of Competitive Inhibitors of LPP Activity—We
recently observed that a phosphothionate analog of LPA that
has, by virtue of its resistance to LPP activity, been employed
as a metabolically stable LPA receptor agonist and was an
effective LPP inhibitor (6). This finding prompted us to search
for compounds that inhibited LPA dephosphorylation without
directly stimulating LPA signaling because of their obvious
potential as tools to probe LPP function. We therefore explored
activities of a series of recently synthesized fluorinated analogs
of LPA and PA on LPP activity (30–32). Structures of four of
these analogs termed XY-3, -4, -13, and -14 are shown in Fig.
4A. XY-3 and -4 are analogs of 2-oleoyl- and 2-palmitoyl-LPA
with a difluoromethyl group at the sn-1 position but an unmod-
ified phosphomonoester group. Compounds XY-13 and -14 are a
pair of enantiomeric analogs of dioleoyl-PA with a phospha-
tase-resistant difluoromethylenephosphonate group replacing
the sn-3 phosphate group. Detergent extracts of membranes
from insect cells infected with baculovirus vectors for expres-
sion of human LPP1, LPP2, and LPP3 can be used for kinetic
analysis of these enzymes using mixed micelles of detergent
and phospholipid. In this assay system LPP activity is depend-
ent on both the bulk and surface concentrations of substrates
(18). At a detergent concentration of 3.4 mM, apparent Km
values for hydrolysis of LPA by these enzymes are in the range
of 1.1–1.4 mol%. We therefore initially examined effects of a
fixed concentration of 10 M of each of these PA analogs on LPP
activity measured at an initial concentration of 0.1, 1.0, and 10
mol% LPA (corresponding to final concentrations of 3.4, 34, and
340 M LPA). XY-3 and XY-4 had no significant effect on LPP1
activity at high mol fractions of substrate and produced a very
modest inhibition at low mol fractions of substrate. By contrast,
compounds XY-13 and XY-14 produced a significant inhibition
of LPP1 activity at all concentrations tested. Inhibition was
more pronounced at lower LPA concentrations suggesting a
competitive mode of inhibition (Fig. 4B). In this assay, XY-13
and -14 inhibited LPP2 and LPP3 activity in an identical man-
ner to that observed for LPP1 (not shown). To examine the
mechanism of this inhibition directly we determined LPP1
activity at increasing LPA concentrations in assays containing
a fixed concentration of 3.4 mM detergent and increasing con-
centrations of XY-14. In this assay system, LPP1 activity in-
creased with substrate concentration and the apparent Km
obtained from fitting the data to the Michaelis-Menten equa-
tion was 0.2 M. Increasing concentrations of XY-14 produced a
marked inhibition of LPP1 activity (Fig. 4C). These data sug-
gest that XY-14 is acting as a pure competitive inhibitor of
LPP1 activity, because inhibition was accompanied by an in-
crease in apparent Km without changing the apparent Vmax of
FIG. 3. Capture of LPP activity and LPP1 protein after surface
biotinylation of resting and LPA-stimulated platelets. A, LPA
phosphatase activities were determined in extracts and avidin-captured
material from resting and LPA-activated platelets that had been incu-
bated in the presence (gray bars) or absence (white bars) of sulfo-NHS-
biotin. The data shown are means  S.D. of triplicate determinations
from a representative experiment. B, detergent-extracted proteins or
avidin-captured proteins were obtained from resting or LPA-activated
platelets that had been incubated in the presence or absence of sulfo-
NHS-biotin as indicated. Proteins were separated by SDS-PAGE on a
12.5% gel and analyzed by Western blotting using an LPP1-selective
antibody. C, platelet lysates were fractionated by sucrose density gra-
dient centrifugation. Material from the indicated subfractions was sep-
arated by SDS-PAGE and immunoblotted for the of the well character-
ized platelet membrane proteins GPIIIa, the platelet -granule
membrane protein P-selectin, and LPP1. Results of scanning densitom-
etry are expressed relative to the band density for each protein in total
platelet lysate.
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the enzyme. The Ki value for inhibition of LPP1 by XY-14 in
this assay system obtained from the equation Km(app)  Km/
Ki[I]  Km was 0.4 M suggesting that XY-14 binds to the
enzyme with a similar affinity to that of LPA itself. This finding
is not surprising, because the previously measured Km values
for hydrolysis of PA and LPA by LPP1 are very similar (18).
Similar results were obtained with XY-13 (not shown). Consist-
ent with the results obtained using recombinant LPP1, XY-14
was an effective inhibitor of LPP activity measured in deter-
gent extracts of platelet membranes and in LPP1 immunopre-
cipitates isolated from these extracts (not shown).
Although the detergent micelle assay system allowed us to
determine the mechanism by which XY-14 inhibited LPP ac-
tivity, use of the compound with intact platelets would neces-
sarily require detergent-free conditions. Preincubation of
washed platelets with 10 M XY-14 in 0.1% BSA produced a
decrease of 10-fold in the rate of dephosphorylation of 1 M
LPA (Fig. 4D). However, consistent with the results obtained
using recombinant LPP1 compounds, XY-3 and XY-4 had no
significant effect on the rate of dephosphorylation of LPA by
intact platelets (not shown).
None of the defined LPA receptors are responsive to PA, and
all three LPA receptors show stereoselective recognition of LPA
analogs at the sn-2 position of the glycerol backbone (35). It is
therefore not surprising that at concentrations up to 10 M
XY-14 is not an agonist for LPA1, LPA2, or LPA3.2 As de-
scribed below, at concentrations up to 10 M XY-14 does not
activate platelet shape change or aggregation responses and
can therefore be used to investigate the consequences of LPP1
inhibition on platelet function.
Inhibition of LPP1 Activity Amplifies Platelet Responses to
LPA—Within seconds to minutes of exposure to exogenous
LPA, platelets exhibit Rho-dependent actin reorganization and
shape change and aggregation (36). We sought to determine
whether inhibition of platelet LPP activity would alter these
responses to LPA. To measure effects on actin reorganization,
platelets were incubated with immobilized fibrinogen under
conditions were unstimulated platelets adhere but the majority
do not fully spread (which is defined here as being character-
ized by actin reorganization and the assumption of a polygonal
shape). Platelet spreading is promoted by agonists. Maximally
effective concentrations of ADP (10 M) or LPA (1 M) increased
the number of spread platelets by 3.7-fold and 1.8-fold (p 
0.001 and p  0.02 versus untreated platelets, respectively)
(Fig. 5, A–C). At concentrations up to 10 M, XY-14 alone had
no effect on platelet spreading and did not significantly alter
ADP-induced platelet spreading. However, in the presence of
XY-14 LPA-stimulated platelet spreading was significantly
(p  0.02) enhanced (to a 2.5-fold increase over resting plate-
lets), and we observed that under these conditions 13% of the
spread platelets were “large spread” platelets, defined as plate-
lets with an area at least twice that of the mean of the area
occupied by ADP-spread platelets (Fig. 5D). These “large
spread” platelets were not observed under any of the other
conditions tested (see Table III for summarized results from
replicate experiments). To probe the mechanism responsible for
this augmentation of platelet shape change responses to LPA
by XY-14, we measured Rho activation in fibrinogen-adherent
platelets under resting conditions or following exposure to ADP
2 R. Janoz, G. D. Prestwich, A. J. Morris, and K. R. Lynch, unpub-
lished observations.
FIG. 4. Inhibition of LPP1 activity by PA and LPA analogs. A, structures of PA and LPA analogs used in this study. B, phosphatase activity
of LPP1 in detergent extracts of membranes from baculovirus-infected sf9 cells was determined using LPA substrate presented as a component of
mixed micelles of Triton X-100 at mol% values of 10, 1, and 0.1. The concentration of XY-3, -4, -13, and -14 was 10 M. The activities shown are
initial rates of substrate dephosphorylation expressed as a percentage of the rate of dephosphorylation observed in the absence of any inhibitor.
The data shown are means  S.D. of triplicate determinations. C, using detergent extracts from baculovirus-infected insect cell membranes as a
source of enzyme, LPP1 activity was determined as the mol fraction of substrate in the mixed substrate, and Triton X-100 micelles were varied in
the presence of increasing concentrations of XY-14. The activities are initial rates of dephosphorylation (less than 20% substrate hydrolysis) and
are means of duplicate determinations. D, intact platelets were preincubated in Tyrode’s solution containing 0.1 mg/ml BSA with (Œ) or without
(), 10 M XY-14 for 5 min before addition of 1 M [32P]LPA. Dephosphorylation was determined as described in the text. The data are means of
duplicate determinations.
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or LPA in the presence or absence of XY-14 using a rhotekin
binding assay. Exposure of platelets to ADP or LPA increases
the fraction of platelet Rho in the activated state. LPA-induced
Rho activation was significantly greater (p  0.05) in the pres-
ence of XY-14 (Fig. 5E). Potentiation of LPA-induced Rho acti-
vation by XY-14 may therefore underlie the enhanced platelet
shape change responses observed in the presence of the LPP
inhibitor.
Next, we tested the effects of XY-14 pretreatment on LPA- or
ADP-induced platelet aggregation. Platelets isolated from mul-
tiple donors were stimulated with LPA. As has been observed
by others, stimulation of aggregation by LPA was concentration-
dependent (Fig. 6). In all but three platelet preparations, we
observed that preincubation with XY-14 resulted in an 2- to
3-fold potentiation of the aggregation response to LPA (Fig. 6,
A and B). It is presently unclear why platelets from three
donors were much less responsive to LPA. In all cases, XY-14
alone had no effect on platelet aggregation or on aggregation
induced by ADP (Fig. 6, A and B). We also measured LPA-
induced Rho activation in platelets that displayed a potentia-
tion of LPA-induced aggregation by XY-14. The results ob-
tained show that LPA-induced Rho activation is both greater
and more persistent in the presence of XY-14 (Fig. 6C). These
results show that XY-14 selectively potentiates platelet shape
change and aggregation responses to LPA and suggest that the
mechanism may involve enhanced activation of Rho.
Inhibition of LPP1 Activity Amplifies Agonist-promoted LPA
Production by Platelets—Thrombin-stimulated platelets gener-
TABLE III
Effect of XY-14 on platelet shape change responses to agonists
Platelets were incubated with fibrinogen-coated slides under resting
conditions or with stimulation by 1 M ADP or 1 M LPA alone or in
combination with 10 M XY-14. Spread platelets, which assume a
polygon shape with a number of filopodia-like projections, were identi-
fied by TRITC-phalloidin staining of actin fibers. A “large spread”
platelet is marked by an arrowhead in panel D of Fig. 5. The table
summarizes data obtained from a series of experiments obtained using










Resting 10.8  3.2 0
ADP 39.6  3.9 0
ADP plus XY-14 37.1  3.3 0
LPA 18.4  2.8 0
XY-14 9.0  3.5 0
LPA plus XY-14 25.3  7.1 3.2  0.4
FIG. 5. Effect of XY-14 on platelet shape change and Rho acti-
vation responses to agonists. Platelets were incubated with fibrin-
ogen-coated slides under resting conditions (A) or with stimulation by
10 M ADP (B) or 1 M LPA (C) alone or in combination with 10 M
XY-14 (D). Spread platelets, which assume a polygon shape with a
number of filopodia-like projections, were identified by TRITC-phalloi-
din staining of actin fibers. A “large spread” platelet is marked by an
arrowhead in panel D. E, Rho activation was determined in resting
adherent platelets or adherent platelets treated with ADP LPA or LPA
plus XY14 using a rhotekin binding assay as described in the text. Total
and activated Rho proteins were separated by SDS-PAGE and detected
by Western blotting. Total and activated Rho were quantitated by
scanning densitometry. Increases in active Rho (expressed as a fraction
of total Rho) were normalized to the fraction of Rho in the active state
in resting platelets.
FIG. 6. Effect of XY-14 on agonist-stimulated platelet aggrega-
tion and Rho activation. Platelet aggregation responses were meas-
ured using the procedures described in the text. Platelets were stimu-
lated with 2.5 M ADP and the indicated concentrations of LPA in the
absence (A) or presence (B) of 2.5 M XY-14. The time scale markers
represent minute intervals. The data shown are representative of sets
of experiments performed using platelets obtained from six separate
donors. C, time courses of Rho activation were measured in platelets in
suspension that were stimulated with LPA in the presence or absence of
XY-14 as indicated. Total and activated Rho proteins were resolved by
SDS-PAGE and visualized by Western blotting and quantitated by
scanning densitometry. Increases in active Rho (expressed as a fraction
of total Rho) were normalized to the fraction of Rho in the active state
in platelets stimulated for 1 min with LPA in the presence of XY-14. The
data shown are means  S.D. of triplicate determinations.
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ate LPA, which accumulates in the incubation medium (10).
LPA production by thrombin-stimulated platelets is, in com-
parison to other indices of platelet activation, relatively slow
being maximal after 1–2 h. [32P]PO4
2-labeled platelets were
treated with vehicle, 10 M XY-14 alone, and thrombin receptor
agonist peptide (TRAP) in the presence and absence of 10 M
XY-14. LPA production in the incubation medium was deter-
mined by lipid extraction and thin layer chromatography with
quantitation made using a PhosphorImager. XY-14 had no
effect on LPA production in these assays, but, in agreement
with reports from several other groups, TRAP stimulated an
accumulation of LPA in the incubation medium that was max-
imal after 1 h and then declined over the second hour of incu-
bation (10). In the presence of XY-14, TRAP-stimulated LPA
production was both more rapid and persistent. In the presence
of XY-14, maximal LPA accumulation was increased 1.8-fold
(Fig. 7A). In a second experiment we measured LPA production
60 and 120 min after stimulation with vehicle or TRAP in the
presence or absence of XY-14. In this experiment at 60 min
TRAP-stimulated LPA production was increased by 1.5-fold in
the presence of XY-14, and the XY-14-dependent increase in
LPA production was more pronounced (3-fold) at 120 min (Fig.
7B). These results suggest that LPP activity opposes pathways
responsible for production of LPA by agonist-activated
platelets.
DISCUSSION
Although the LPP enzymes are structurally simple proteins
that catalyze well defined enzymatic reactions, ongoing studies
continue to associate them with a surprisingly complex range of
biological functions. At the cellular level, overexpression stud-
ies suggest that LPPs 1–3 act as both negative regulators of
LPA and S1P signaling and have roles in metabolism of intra-
cellular lipid messengers (23, 37). At the organismal level,
inactivation or misexpression of two Drosophila LPP enzymes
alters gem cell migration in early development, which has been
suggested to involve localized changes in LPP-catalyzed degra-
dation of an as yet unidentified lipid signaling molecule (21).
Although genetic inactivation of LPP2 in mice produces no
obvious phenotype, inactivation of the LPP3 gene results in
early embryonic lethality resulting from defects in vasculariza-
tion and patterning (27, 38). Furthermore, there are hints that
LPPs may have actions that are independent of their catalytic
activities. Effects of LPP3 inactivation in mice are similar to
those seen when wnt signaling is up-regulated and LPP3 in-
hibits wnt signaling in cultured cells (27). LPP3 has also been
shown to serve as an integrin ligand that regulates cell-cell
interactions through a unique RGD sequence in the second
extracellular loop (26). Clearly, more subtle approaches are
required to separate activity-dependent and independent func-
tions of these proteins. We report the identification of chemical
inhibitors of LPP activity that can be used to probe the role
hydrolysis of phospholipid substrates by endogenously ex-
pressed LPPs. Results using one such compound to investigate
effects of inhibition of LPP activity in platelets identify roles for
LPPs in control of both platelet responses to LPA and of LPA
production by activated platelets. These findings are signifi-
cant, because they suggest a physiological role for LPPs in
controlling platelet and by implication possibly also vascular
function. Our results also provide new insight into the physio-
logical function of LPPs that may explain some of their complex
biological activities.
Platelets are highly responsive to LPA and play both direct
and indirect roles in the mechanisms responsible for LPA syn-
thesis in the blood. We found that platelets actively dephospho-
rylate LPA. Immunological analysis reveals that LPP1 is
strongly expressed by platelets and that expression of LPP3 is
restricted to a subpopulation of 5% of platelets. Heterogene-
ous has been observed for other platelet surface proteins and
may relate to differences in platelet age and agonist respon-
siveness (39). Indirect immunofluorescence studies reveal that
the localization of LPP1 and LPP3 is different in LPA-activated
platelets, and comparisons with resting platelets suggest that
LPP1 redistributes across the platelet surface when agonist-
activated platelets spread on a fibrinogen surface. LPA in-
creases the amount of LPP1 activity and protein accessible to
labeling by a cell-impermeant biotin derivative suggesting that
platelet activation is accompanied by translocation of LPP1 to
the platelet surface which may have a role in adaptive re-
sponses to activation of platelets by lysophospholipid agonists.
Cell surface localization has been reported for both overex-
pressed and endogenous LPPs 1–3 in several mammalian cell
types (18–20, 23, 24). Plasma membrane localization LPP1 has
been associated with increased cell surface LPP activity and
specific decreases in rapid signaling responses to activation of
LPA and S1P receptors (19, 22). In cases where overexpression
of LPP1 resulted in attenuation of rapid LPA signaling re-
sponses (i.e. responses that are manifest over seconds to min-
utes), notably phospholipase C activation and consequent Ca2
mobilization, the effects were observed under conditions where
the fraction of extracellularly added LPA degraded was much
too small to account for the decreased response. These findings
led to the proposition that LPPs restrict access of a localized
pool of LPA to LPA receptors possibly by controlling LPA levels
associated with the outer leaflet of the plasma membrane (22,
37). Here we found that preincubation of platelets with a flu-
orophosphonate analog of PA under conditions that substan-
tially inhibit LPP activity resulted in a potentiation of two
platelet functional responses to LPA, aggregation and shape
change. In both cases these effects were observed when plate-
lets were stimulated with maximally effective concentrations of
LPA and, based on the duration of these assays and on the
small numbers of platelets used, even in the absence of the
inhibitor, hydrolysis of LPA in the incubation media would be
FIG. 7. Effect of XY-14 on LPA production by agonist stimu-
lated platelets. A, platelets were labeled with [32P]PO4
2, washed, and
then incubated with vehicle (), 10 M XY-14 (f), or 10 M TRAP alone
(Œ) or in combination with 10 M XY-14 (). Radioactivity associated
with LPA released into the incubation medium was quantitated by
PhosphorImager scanning after separation by thin layer chromatogra-
phy. The data are single LPA determinations and representative of
three separate experiments. B, platelets were incubated for 60 min
(white bars) or 120 min (gray bars) in the presence or absence of 10 M
TRAP with and without 10 M XY-14 as indicated, and LPA production
was determined. The data shown are means  S.D. of triplicate deter-
minations from a single experiment.
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less than 0.1% of the total present at the beginning of the
experiment. Because we used concentrations of LPA that are
maximally effective in the absence of the inhibitor, this result
also makes it unlikely that the potentiation observed is due to
a nonspecific increase in bioavailability of LPA. Our findings
are, therefore, consistent with this “restricted access” model
and extend the overexpression studies that data in support of
this model to show that LPP inhibition potentiates rapid LPA
signaling responses to LPA in a manner that cannot be ac-
counted for by preservation of LPA in the medium. Testing this
model will be challenging; levels of cell surface-associated LPA
are small and, once LPA partitions into the plasma membrane,
dephosphorylation of LPA is rapid (29).
Other work has shown that overexpression of LPPs results in
attenuation of cell growth and survival responses to LPA,
which occur with much longer time courses than the rapid
responses discussed above (6, 24). In comparison to LPA, LPP-
resistant LPA analogs have been found to exhibit increased
potency in cell proliferation assays that likely results from
their resistance to metabolic degradation (24). Transient or
stable overexpression of LPP3 in cultured ovarian cancer cells
results in decreased growth in a colony forming assay and an
increase in the rate of apoptosis. Most strikingly, co-culture of
LPP3-expressing cells with their parental counterparts de-
creased growth of the parental cells. This action of LPP3 can
most simply be explained by a decrease in levels of an extra-
cellular mediator, most likely LPA, because the decrease in
growth could be rescued by addition of a hydrolysis-resistant
LPA analog (6). These results indicate that LPPs can also
modulate LPA signaling “in trans”; i.e. LPP activity in one cell
can alter LPA signaling in another. Our observation that inhi-
bition of LPP1 activity potentiates LPA production by platelets
suggests that this “trans” action of LPPs involves the degrada-
tion of extracellular LPA and possibly also the opposition of
pathways responsible for LPA production. Precisely how LPP
inhibition potentiates LPA production by activated platelets is
not clear. The simplest explanation would be that the role of
LPP in the process is indirect: in the presence of an LPP
inhibitor LPA produced in response to agonists is simply pro-
tected from degradation. Alternatively, one of the mechanisms
proposed to account for LPA production by isolated platelets is
the hydrolysis of phosphatidic acid by phospholipase A2. Evi-
dence that the source of this PA is micoparticles released by
activated platelets has been presented, and our finding that
LPP activity is enriched in these microparticles suggests the
possibility that inhibition of LPP activity could produce ele-
vated LPA production through increases in PA levels.
Our finding that LPPs can oppose LPA production may ex-
plain some intriguing information about LPP function from
developmental studies in Drosophila. In the developing fly
embryo the germ cells are specified on the surface, and these
cells move into the gut upon gastrulation. The germ cells mi-
grate actively through the gut and then through the mesoderm
to pair with their somatic counterparts to form the gonad. Two
Drosophila LPP homologs, Wunen-1 and Wunen-2, are nor-
mally expressed in tissues that repel germ cells. Germ cell
migration and survival are disrupted in a Drosophila mutant,
wunen, in which these genes are inactivated. Ectopic expres-
sion of either Wunen gene in the mesoderm repels migrating
germ cells (21, 25). Wunen-2 is a functional LPP that hydro-
lyzes LPA, and the integrity of its catalytic domain is required
for these effects (Starz-Gaiano, et al. (21)).3 The simplest ex-
planation of these data is that catalytic activity of the wunen
genes destroys or opposes the synthesis of an as yet undefined
factor that is required for germ cell survival and migration.
XY-14 inhibits hydrolysis of LPA by Wunen-2,4 and it will be
interesting to see if exposure of Drosophila embryos to this
compound recapitulates the wunen germ cell migration
phenotype.
The identification of LPP1 as a pivotal regulator of LPA
production and signaling in platelets suggest that this enzyme
may function to control circulating LPA levels and possibly also
regulate localized changes in LPA levels resulting from platelet
activation. Because of the well defined actions of LPA on plate-
lets, various inflammatory cell types, vascular smooth muscle
cells, and endothelial cells, there is considerable interest in the
possibility that LPA functions in vascular responses to injury
and may also be a relevant thrombo- and atherogenic molecule
in cardiovascular disease (3, 5). The lack of LPA receptor-
selective agonists and antagonists and the apparent functional
redundancy among the known LPA receptors inferred from
gene inactivation studies in mice is hampering efforts to test
these ideas explicitly (40). Assignment of specific responses to
particular LPA receptor subtypes continues to be a challenge,
and although platelets are clearly highly responsive to LPA the
identity of the receptor involved is unclear (24). Similarly,
although acute vascular responses have been observed in re-
sponse to injection of LPA (41), the physiological sites of LPA
synthesis and action in the cardiovascular system are not
known (3). The LPP inhibitor reported here may prove to be a
valuable tool to potentiate LPA signaling in response to endo-
genously formed LPA and thereby address this critical and
longstanding issue.
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